Openly accessible

The use of sensitive chemical antibodies for diagnosis: detection of low levels of Epcam in breast cancer

Shigdar, Sarah, Qian, Christine, Lv, Li, Pu, Chunwen, Li, Yong, Marappan, Manju, Lin, Jia, Wang, Lifen and Duan, Wei 2013, The use of sensitive chemical antibodies for diagnosis: detection of low levels of Epcam in breast cancer, PLoS One, vol. 8, no. 2, pp. 1-8.

Attached Files
Name Description MIMEType Size Downloads
shigdar-useofsensitive-2013.pdf Published version application/pdf 8.71MB 68

Title The use of sensitive chemical antibodies for diagnosis: detection of low levels of Epcam in breast cancer
Author(s) Shigdar, Sarah
Qian, Christine
Lv, Li
Pu, Chunwen
Li, Yong
Marappan, Manju
Lin, Jia
Wang, Lifen
Duan, Wei
Journal name PLoS One
Volume number 8
Issue number 2
Start page 1
End page 8
Total pages 8
Publisher Public Library of Science
Place of publication San Diego, United States
Publication date 2013-02
ISSN 1932-6203
Keyword(s) epithelial cancers
immunotherapy trials
tumors
aptamers
histopathological diagnosis
Summary EpCAM is expressed at low levels in a variety of normal human epithelial tissues, but is overexpressed in 70–90% of carcinomas. From a clinico-pathological point of view, this has both prognostic and therapeutic significance. EpCAM was first suggested as a therapeutic target for the treatment of epithelial cancers in the 1990s. However, following several immunotherapy trials, the results have been mixed. It has been suggested that this is due, at least in part, to an unknown level of EpCAM expression in the tumors being targeted. Thus, selection of patients who would benefit from EpCAM immunotherapy by determining EpCAM status in the tumor biopsies is currently undergoing vigorous evaluation. However, current EpCAM antibodies are not robust enough to be able to detect EpCAM expression in all pathological tissues.

Here we report a newly developed EpCAM RNA aptamer, also known as a chemical antibody, which is not only specific but also more sensitive than current antibodies for the detection of EpCAM in formalin-fixed paraffin-embedded primary breast cancers. This new aptamer, together with our previously described aptamer, showed no non- specific staining or cross-reactivity with tissues that do not express EpCAM. They were able to reliably detect target proteins in breast cancer xenograft where an anti-EpCAM antibody (323/A3) showed limited or no reactivity. Our results demonstrated a more robust detection of EpCAM using RNA aptamers over antibodies in clinical samples with chromogenic staining. This shows the potential of aptamers in the future of histopathological diagnosis and as a tool to guide targeted immunotherapy.
Language eng
Field of Research 110316 Pathology (excl Oral Pathology)
Socio Economic Objective 920102 Cancer and Related Disorders
HERDC Research category C1 Refereed article in a scholarly journal
HERDC collection year 2013
Persistent URL http://hdl.handle.net/10536/DRO/DU:30055093

Document type: Journal Article
Collections: School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in TR Web of Science
Scopus Citation Count Cited 2 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 28 Abstract Views, 68 File Downloads  -  Detailed Statistics
Created: Fri, 23 Aug 2013, 11:19:46 EST by Barb Lavelle

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.